Sunday, July 20, 2008

DDAVP Spray (desmopressin acetate nasal spray) and DDAVP Rhinyle (desmopressin acetate nasal solution)

From Health Canada:

Ferring Pharmaceuticals, in cooperation with Health Canada, wishes to inform Canadians about new safety information regarding desmopressin when it is used nasally for the treatment of bedwetting (also called Primary Nocturnal Enuresis or PNE). Because of increased risk of serious side effect with all nasal formulations, they are no longer indicated for use in patients with bedwetting.

Desmopressin can cause water retention that could lead to a low blood sodium level (hyponatremia). Hyponatremia is rare but serious and if unrecognized, can lead to seizures and even death.
For Health Professionals
For the Public

No comments: